Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Doctor Peset (9)

2024

  1. Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©

    Ophthalmology and Therapy, Vol. 13, Núm. 6, pp. 1669-1682

2023

  1. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  2. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2022

  1. Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study

    BMJ open, Vol. 12, Núm. 3, pp. e051378

  2. Vogt-Koyanagi-Harada disease in Spain

    European Journal of Ophthalmology, Vol. 32, Núm. 3, pp. 1547-1554

2020

  1. Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy

    Ocular Immunology and Inflammation, pp. 1-8

  2. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group

    Ophthalmology

2017

  1. Development of an activity disease score in patients with uveitis (UVEDAI)

    Rheumatology International, Vol. 37, Núm. 4, pp. 647-656

2014

  1. AB0571 High Dose Intravenous Methylprednisolone Induces RAPID Improvement in Severe Ocular Inflammation. Multicenter Study of 104 Cases

    Annals of the Rheumatic Diseases, Vol. 73, Núm. Suppl 2, pp. 995.1-995